Royalty Pharma (RPRX) Expected to Announce Earnings on Tuesday

Royalty Pharma (NASDAQ:RPRX) is projected to announce its earnings results before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of $0.99 per share and revenue of $743.60 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $31.73 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The business’s 50 day simple moving average is $27.83 and its 200 day simple moving average is $27.64. Royalty Pharma has a 12 month low of $24.05 and a 12 month high of $32.21. The company has a market cap of $18.69 billion, a price-to-earnings ratio of 16.44 and a beta of 0.49.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date is Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Wall Street Analysts Forecast Growth

RPRX has been the topic of a number of research reports. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup dropped their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and an average target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.